Your browser is no longer supported. Please, upgrade your browser.
BNTX [NASD]
BioNTech SE
Index- P/E4.68 EPS (ttm)33.45 Insider Own66.88% Shs Outstand244.37M Perf Week-7.53%
Market Cap40.27B Forward P/E4.40 EPS next Y35.56 Insider Trans0.00% Shs Float215.94M Perf Month-38.70%
Income8.47B PEG- EPS next Q7.74 Inst Own17.40% Short Float1.00% Perf Quarter-46.94%
Sales15.60B P/S2.58 EPS this Y107.10% Inst Trans1.30% Short Ratio0.62 Perf Half Y-44.90%
Book/sh40.32 P/B3.88 EPS next Y-3.38% ROA100.20% Target Price319.82 Perf Year47.23%
Cash/sh10.52 P/C14.87 EPS next 5Y- ROE165.70% 52W Range90.29 - 464.00 Perf YTD-39.30%
Dividend- P/FCF29.07 EPS past 5Y- ROI4.90% 52W High-66.27% Beta-
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin91.50% 52W Low73.32% ATR16.15
Employees2800 Current Ratio2.80 Sales Q/Q8918.20% Oper. Margin78.50% RSI (14)29.12 Volatility8.87% 7.70%
OptionableYes Debt/Eq0.03 EPS Q/Q- Profit Margin54.30% Rel Volume1.16 Prev Close150.98
ShortableYes LT Debt/Eq0.03 EarningsNov 09 BMO Payout0.00% Avg Volume3.47M Price156.49
Recom2.50 SMA20-25.43% SMA50-39.42% SMA200-39.81% Volume4,020,347 Change3.65%
Dec-16-21Initiated Morgan Stanley Equal-Weight $294
Nov-10-21Upgrade H.C. Wainwright Neutral → Buy $360
Oct-22-21Initiated Deutsche Bank Hold $250
Oct-07-21Initiated Jefferies Hold $230
Aug-11-21Upgrade Bryan Garnier Neutral → Buy $451
Jul-19-21Resumed Wolfe Research Outperform $248
Jun-16-21Downgrade Redburn Neutral → Sell $146
May-18-21Initiated Goldman Neutral $173
May-11-21Downgrade Bryan Garnier Buy → Neutral $135 → $206
Dec-01-20Downgrade BofA Securities Buy → Neutral $123 → $126
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Jan-25-22 04:43PM  
04:09PM  
10:38AM  
10:10AM  
09:09AM  
08:58AM  
08:15AM  
07:45AM  
07:00AM  
06:45AM  
06:45AM  
Jan-24-22 10:01AM  
07:00AM  
Jan-21-22 03:47PM  
03:15PM  
01:59PM  
01:47PM  
10:55AM  
10:49AM  
12:06AM  
Jan-20-22 04:59PM  
04:35PM  
04:08PM  
03:43PM  
11:55AM  
11:34AM  
11:31AM  
11:28AM  
10:44AM  
10:35AM  
Jan-19-22 04:03PM  
11:29AM  
10:27AM  
10:00AM  
08:20AM  
07:34AM  
Jan-18-22 04:11PM  
03:19PM  
02:57PM  
01:38PM  
11:34AM  
02:03AM  
Jan-14-22 02:12PM  
05:24AM  
Jan-13-22 06:17PM  
11:49AM  
10:53AM  
10:29AM  
10:25AM  
07:00AM  
Jan-12-22 11:10AM  
09:38AM  
09:35AM  
07:29AM  
Jan-11-22 04:33PM  
03:33PM  
01:52PM  
11:18AM  
10:32AM  
10:31AM  
10:31AM  
10:25AM  
10:25AM  
10:24AM  
10:04AM  
09:58AM  
09:49AM  
08:17AM  
07:47AM  
07:38AM  
07:26AM  
07:00AM  
Jan-10-22 05:03PM  
04:27PM  
03:37PM  
02:52PM  
10:21AM  
10:18AM  
09:45AM  
08:00AM  
05:09AM  
05:01AM  
Jan-07-22 04:26PM  
02:59PM  
11:25AM  
11:17AM  
Jan-06-22 04:31PM  
11:52AM  
10:07AM  
04:14AM  
Jan-05-22 09:40PM  
09:04PM  
06:08PM  
04:22PM  
02:03PM  
09:55AM  
07:44AM  
07:07AM  
06:56AM  
06:45AM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.